



UNIVERSITÀ  
DEGLI STUDI  
DI BRESCIA

# Oral Potentially Malignant Disorders (OPMD): state of the art and a roadmap for research

Brescia – Italy, February 25th





**Welcome to the 1st European Congress on Oral Potentially Malignant Disorders (OPMDs), Brescia, 25th February 2022.**

*There is an arising interest on premalignant lesions: the malignant transformation pathways need to be better elucidated, as well as the predictive factors must be implemented, so to offer a better knowledge of the preclinical aspects of this disease. Similarly, the clinical aspects of OPMDs need to be studied, as at the moment no approved and efficacious preventive treatment is available. Therefore, OPMDs offer interesting landscapes for a multidisciplinary approach involving biomolecular experts, pathologists, surgeons, medical oncologists, pharmacologists, as well as experts in design of clinical trials.*

*Keynote Lectures will deal with pathological, molecular and clinical issues, suggesting a strict integration with the aim to investigate new fields of research and transpose the latest findings into practice. Moreover, a round table on ethical issues and an overview about next steps to implement research is scheduled. An appropriate time will be dedicated to the presentation of abstract and ongoing research on OPMDs, so to offer the possibility to present the latest research and to receive feedback, so to increase the cooperation with other research groups.*

*We will be honoured to host in **Brescia** a limited number of participants and the congress will be available also in live streaming.*

*This Congress will hopefully pave the way towards the institution of a European Network on OPMDs, committed to enhance Preclinical and Clinical research and consequently scientific knowledge on this topic.*

***We are very excited to meet you and to increase research on OPMDs!***

The Scientific Board and Secretariat

# PROGRAM

08.30 - 08:45

Registration

08.45 - 09:00

Welcome

## Overview on main topics in OPMD research

From 09.00 to 10.00

### Risk classification:

*Moderators: Simonetta Battocchio - Chiara Romani*

- Pathological classification - *Senada Koljenovic*
- Genomic classification - *Ruud Brakenhoff*
- Phenotypic classification – *Pierre Saintigny*
- Discussion

From 10.00 to 11.00

### Preclinical models:

*Moderators: Alessandra Majorana - Laura Ardighieri*

- Preclinical research: state of the art and models for research (cell cultures, organoids, animal models) - *Moshe Elkabets*
- Role of microenvironment - *Leon Van Kempen*
- Role of oral microbiome – *Jukka Meurman*
- Discussion (15 min)

From 11.00 to 11.30

Break

From 11.30 to 13.00

### Clinical characteristics and management:

*Moderators: Jebrane Bouaoud - Davide Mattavelli*

- Clinical classification and terminology - *Erik van der Mey*

- Biological endoscopy in detection of OPMD - *Cesare Piazza, Alberto Paderno*
- Practical insights from oral medicine - *Noam Yarom*
- Ongoing clinical research in OPMD – *Paolo Bossi*
- Discussion

From 13.00 to 14.00

Lunch Break

### Round table and abstract presentation

From 14.00 to 15.00

14:00-14:15 Introduction to set the stage for the round table: *Ruud Brakenhoff*

**Round table** *Chaired by Alberto Deganello*

*Sandra Sigala - Elena Bardellini - Ruud Brakenhoff - Antonella Cardone (ECPC)*

Current shortcomings of studies and ethical issues in clinical trial design in premalignant disorders

From 15.00 to 15.30

Break

From 15.30 to 17.00

**Abstract presentations**

*Moderators: Chloe Bertolus - Sara Bonini*

**Oral presentation of selected abstracts and ongoing research on OPMD**

- Analysis of infrared absorbance spectra identifies the transformation potential of oral epithelial dysplasia (*B.G. Ellis, J.M. Risk, C.A. Whitley, A. Triantafyllou, P.J. Gunning, C.I. Smith, S.D. Barrett, P. Gardener, R.J. Shaw, P. Weightman - U.K*)
- Effectiveness of a non-invasive salivary diagnostic test for early identification of potentially malignant lesions and squamocellular carcinoma of the oral cavity: quantitative and qualitative evaluation of salivary markers CD44 and total proteins (*L. Rosselli, J. Merlo, F. Amadori, E. Bardellini, A. Majorana - Italy*)

From 15.30 to 17.00

- SAVER: Sodium Valproate for the Epigenetic Reprogramming of High-Risk Oral Epithelial Dysplasia. A Phase II randomised controlled clinical trial (*C.E. McCarthy, S. Fedele, S. Cicconi, M. Ho, M. Robinson, J. Perry, S. Porter, B. Greenhalf, S. Chauhan, R. Jackson, B. Young, F. Sherratt, T. Liloglou, J. Sacco, R.J. Shaw - U.K*)
- Optical Coherence Tomography (OCT) and Oral Potentially Malignant Disorders: critical review on potential diagnostic patterns (*F. Buttacavoli, M. Coppini, G. Seminara, R. Mauceri, O. Di Fede, G. Campisi, V. Panzarella - Italy*)
- Identification of an epigenetic profile associated with malignant transformation of oral lichen planus: preliminary study (*D.B. Gissi, A. Sangiovanni, A. Gabusi, R. Rossi, A. Tarsitano, D. Filippini, C. Marchetti, L. Montebugnoli, M.P. Foschini, L. Morandi (Italy)*)
- 13-gene DNA methylation analysis from oral brushing for early detection of malignant and pre-malignant lesions of the oral cavity (*A. Gabusi, A. Tarsitano, D.B. Gissi, R. Rossi, D. Filippini, F. Di Fabio, C. Marchetti, L. Montebugnoli, M.P. Foschini, L. Morandi - Italy*)
- Oral cancer prediction by noninvasive genetic screening (*J.B. Poell, L.J. Wils, A. Brink, R. Dietrich, C. Krieg, E. Velleuer, I. Evren, E.R.E.A. Brouns, J.G.A.M. de Visscher, E. Bloemena, B. Ylstra, R.H. Brakenhoff - the Netherlands*)
- Oral cavity carcinoma in patients with and without a history of lichen planus: a comparative analysis of clinical and pathological characteristics (*O. Iocca, L. Sedran, P. Garzino-Demo, C. Copelli, S. Rubattino, F. Volpe, P.G. Arduino - Italy*)

From 17.00 to 17.30

**Presentation of European network on OPMD**

*Paolo Bossi - Pierre Saintigny – Senada Koljenovic*

# GENERAL INFORMATION

## CONGRESS VENUE

Aula Magna Facoltà di Medicina Brescia University, Via Europa 11

## HOW TO GET TO THE CONGRESS VENUE

**AIRPORT:** Milan Bergamo is at 35 Km Milan Linate is at 90 km Milan Malpensa is at 150 km

**TRAIN:** Brescia train station Metro STAZIONE FS STOP

**HIGHWAY:** Exit Brescia Ovest or Brescia Centro

**METRO:** The best way to reach the Congress Venue is by Metro – EUROPA STOP

## TRAVEL SERVICE

We are proud to offer delegates services that should facilitate their travel arrangements, for any need please refer to Organizing Secretariat [info@studioprogress.it](mailto:info@studioprogress.it)



# GENERAL INFORMATION

## ONSITE Registration

Due to COVID RESTRICTION the Congress Hall can accommodate a maximum number of **150 participants** **ONSITE**. A COVID Green Pass vaccine passport will be requested in order to enter the Meeting Hall.

## ONLINE Registration

Congress will also be available in live streaming.

Once you register you will receive the link to connect via **zoom** (<https://zoom.us/>) and through the Q&A box you will be able to join live discussion.

## REGULAR REGISTRATION

Vat 22% included

**ONSITE PARTECIPANT: 80€**

**ONLINE PARTECIPANT: 50€**

**ONSITE RESIDENT: 60€**

**ONLINE RESIDENT: 35€**

## REGISTRATION DESK

OPENING HOURS: Friday 25th February, 08.00 – 18.00

**GREEN PASS:** A COVID Green Pass vaccine passport will be requested to enter the Meeting Hall.

**BADGE:** Each participant receives a name badge upon check-in at Registration. As only registered participants will be permitted to attend the scientific sessions, you are required to wear your badge when entering and while remaining in the congress venue.

**CERTIFICATE OF ATTENDANCE:** All participants will receive a certificate of attendance.

**LANGUAGE:** The official language of the congress is English. No simultaneous translation is provided.



# FACULTY

Laura Ardighieri- *Italy*  
Elena Bardellini- *Italy*  
Simonetta Battocchio- *Italy*  
Chloé Bertolus - *France*  
Sara Bonini- *Italy*  
Paolo Bossi – *Italy*  
Jebrane Bouaoud – *France*  
Ruud H Brakenhoff - *The Netherlands*  
Antonella Cardone – *Belgium*  
Alberto Deganello- *Italy*  
Moshe Elkabets - *Israel*  
Senada Koljenović – *Belgium/Netherlands*  
Alessandra Majorana- *Italy*  
Davide Mattavelli- *Italy*  
Jukka Meurman - *Finland*  
Alberto Paderno- *Italy*  
Cesare Piazza – *Italy*  
Chiara Romani- *Italy*  
Pierre Saintigny – *France*  
Sandra Sigala- *Italy*  
Erik van der Mey - *The Netherlands*  
Léon C van Kempen - *The Netherlands*  
Noam Yarom – *Israel*

## SCIENTIFIC BOARD

**Paolo Bossi**

Medical Oncology Unit, Department of Medical and Surgical Specialities, Radiological Sciences and Public Health University of Brescia, ASST-Spedali Civili.

**Pierre Saintigny**

Department of Medical Oncology, Centre Léon Bérard, Lyon, France; Univ Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon 69008, France.

**Senada Koljenović**

Department of Pathology, Erasmus University Medical Center, Rotterdam, Netherlands; Erasmus Medical Center Cancer Institute, Erasmus University Medical Center, Rotterdam, Netherlands.

**Ruud H Brakenhoff**

Otolaryngology/Head and Neck Surgery, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Postbus 7057, 1007 MB Amsterdam, The Netherlands.

**Léon C van Kempen**

Department of Pathology & Medical Biology, University of Groningen, University Medical Centre Groningen, Groningen, the Netherlands.

**Chloé Bertolus**

Department Head, Department of Maxillo-Facial Surgery, Sorbonne Université, Hôpital Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France.

**Jebrane Bouaoud**

Department of Maxillo-Facial Surgery, Sorbonne Université, Hôpital Pitié-Salpêtrière, Assistance Publique des Hôpitaux de Paris, Paris, France.

## SCIENTIFIC SECRETARIAT

Cesare Piazza  
Alberto Deganello  
Alberto Paderno  
Davide Mattavelli

Department of Otorhinolaryngology-Head and Neck Surgery, ASST-Spedali Civili di Brescia, University of Brescia, Piazza Spedali Civili 1, 25123, Brescia, Italy;  
Department of Medical, Surgical and Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.

Alessandra Majorana  
Elena Bardellini

Dental Clinic, Oral Medicine Unit - Department of Medical and Surgical Specialties, Radiological Science and Public Health University of Brescia, ASST-Spedali Civili, Brescia, Italy.

Chiara Romani

Angelo Nocivelli' Institute of Molecular Medicine, University of Brescia and ASST-Spedali Civili, Brescia, Italy.

Sandra Sigala  
Sara Bonini

Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

Simonetta Battocchio  
Laura Ardighieri

Unit of Pathology, Department of Molecular and Translational Medicine, University of Brescia, ASST-Spedali Civili, Brescia, Italy

Paolo Bossi  
Cristina Gurizzan  
Luigi Lorini  
Davide Smussi

Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health University of Brescia, ASST-Spedali Civili, Piazzale Spedali Civili 1, 25123, Brescia, Italy.



SANOFI GENZYME  | REGENERON

  
CARLO BIANCHI  
tecnologie chirurgiche

**STORZ**  
KARL STORZ — ENDOSKOPE

**biopharm**  
innovicare

## *Organizing Secretariat*



StudioProgress snc  
Via Cattaneo 51, 25121 Brescia (Italy)  
Tel: (+39) 030 290326 Fax: (+39) 030 2809839  
[www.studioprogress.it](http://www.studioprogress.it)  
[info@studioprogress.it](mailto:info@studioprogress.it)